Publications
2024
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232
Cardiovascular disease, medication regimens and HIV in pregnancy: new research relevant to nurses.
Reynolds, H. E. (2024). Cardiovascular disease, medication regimens and HIV in pregnancy: new research relevant to nurses.. British journal of nursing (Mark Allen Publishing), 33(11), S18-S21. doi:10.12968/bjon.2024.0144
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.
Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., . . . Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.. Journal of pharmaceutical and biomedical analysis, 245, 116155. doi:10.1016/j.jpba.2024.116155
Support, not blame: safe partner disclosure among women diagnosed with HIV late in pregnancy in South Africa and Uganda.
Twimukye, A., Alhassan, Y., Ringwald, B., Malaba, T., Myer, L., Waitt, C., . . . Taegtmeyer, M. (2024). Support, not blame: safe partner disclosure among women diagnosed with HIV late in pregnancy in South Africa and Uganda.. AIDS research and therapy, 21(1), 14. doi:10.1186/s12981-024-00600-z
Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.
van der Wekken-Pas, L., Nassiwa, S., Malaba, T., Lamorde, M., Myer, L., Waitt, C., . . . Colbers, A. (2024). Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.. AIDS (London, England). doi:10.1097/qad.0000000000003852
2023
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233. doi:10.1016/j.jpba.2023.115436
Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS
Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057
Development, Validation and Application of an LC-MS/MS Method for Quantification of Favipiravir in Human Plasma
2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
Donovan-Banfield, I., Penrice-Randal, R., Goldswain, H., Rzeszutek, A. M., Pilgrim, J., Bullock, K., . . . Fletcher, T. (2022). Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-34839-9
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., . . . Khoo, S. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. LANCET HIV, 9(8), E534-E543. doi:10.1016/S2352-3018(22)00173-4
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda
Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). 'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC PREGNANCY AND CHILDBIRTH, 22(1). doi:10.1186/s12884-022-04896-5
<i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda
Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). <i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda. BMC WOMENS HEALTH, 22(1). doi:10.1186/s12905-022-01814-x
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
Ochanda, P. N., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2022). A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00446-3
Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199
An open label, adaptive, phase 1 trial of high‐dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS‐CoV‐2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463
Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in five randomised trials of 1074 pregnant women
Sokhela, S., Venter, F., Bosch, B., Akpomiemie, G., Tembo, A., Pepperrell, T., . . . Hill, A. (2022). Adverse birth outcomes and risk of MTCT for dolutegravir versus efavirenz in five randomised trials of 1074 pregnant women. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 25 (pp. 48-49). Retrieved from https://www.webofscience.com/
Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants
Sokhela, S., Venter, F., Bosch, B., Akpomiemie, G., Tembo, A., Pepperrell, T., . . . Hill, A. (2022). Virological failure and HIV RNA re-suppression rates in four randomised trials of dolutegravir, efavirenz or protease inhibitor-based treatment in 3116 participants. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 25 (pp. 19-20). Retrieved from https://www.webofscience.com/
2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
Dickinson, L., Walimbwa, S., Singh, Y., Kaboggoza, J., Kintu, K., Sihlangu, M., . . . Orrell, C. (2021). Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1. CLINICAL INFECTIOUS DISEASES, 73(5), E1200-E1207. doi:10.1093/cid/ciaa1861
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study
2020
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda
Alhassan, Y., Twimukye, A., Malaba, T., Orrell, C., Myer, L., Waitt, C., . . . Taegtmeyer, M. (2020). Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and Uganda. BMC Public Health, 20(1). doi:10.1186/s12889-020-09991-w
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda
Alhassan, Y., Twimukye, A., Malaba, T., Orrell, C., Myer, L., Waitt, C., . . . Taegtmeyer, M. (2020). Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda. BMC HEALTH SERVICES RESEARCH, 20(1). doi:10.1186/s12913-020-05580-0
AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial
Griffiths, G., Fitzgerald, R., Jaki, T., Corkhill, A., Marwood, E., Reynolds, H., . . . Khoo, S. (2020). AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. TRIALS, 21(1). doi:10.1186/s13063-020-04473-1
COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM
Perez Nicholas, O., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2020). COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM. In VALUE IN HEALTH Vol. 23 (pp. S184). Retrieved from https://www.webofscience.com/
Dolutegravir versus efavirenz when starting HIV therapy in late pregnancy: a randomised controlled trial
Kintu, K., Malaba, T., Nakibuka, J., Papamichael, C., Colbers, A., Byrne, K., . . . Khoo, S. (2020). Dolutegravir versus efavirenz when starting HIV therapy in late pregnancy: a randomised controlled trial. The Lancet HIV, 7(5), e332-e339. doi:10.1016/s2352-3018(20)30050-3
PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM
Perez Nicholas, O., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2020). PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM. Value in Health, 23, S184. doi:10.1016/j.jval.2020.04.553
2019
Oral versus Intravenous Antibiotics for Bone and Joint Infection
Li, H. -K., Rombach, I., Zambellas, R., Walker, A. S., McNally, M. A., Atkins, B. L., . . . Scarborough, M. (2019). Oral versus Intravenous Antibiotics for Bone and Joint Infection. NEW ENGLAND JOURNAL OF MEDICINE, 380(5), 425-436. doi:10.1056/NEJMoa1710926
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt, C., Orrell, C., Walimbwa, S., Singh, Y., Kintu, K., Simmons, B., . . . Khoo, S. (2019). Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLOS MEDICINE, 16(9). doi:10.1371/journal.pmed.1002895
2018
Adjunctive rifampicin for <i>Staphylococcus aureus</i> bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
Thwaites, G. E., Scarborough, M., Szubert, A., Nsutebu, E., Tilley, R., Greig, J., . . . Walker, A. S. (2018). Adjunctive rifampicin for <i>Staphylococcus aureus</i> bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. LANCET, 391(10121), 668-678. doi:10.1016/S0140-6736(17)32456-X
2015
Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir
Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376
2014
The autonomous role of the research nurse
Reynolds, H., Harrison, J., Tamakalo, R., Hoyle, M. C., & Burgess, L. (2014). The autonomous role of the research nurse. HIV Nursing, 14(1), 12-16.
2012
Accuracy of fluorodeoxyglucose positron emission tomography with computed tomography and magnetic resonance spectroscopy in differentiating between primary cerebral lymphoma and non- malignant CNS lesions in HIV infected patients
Hogan, C., Bonington, A., Bonington, S., Carrington, B., Julyan, P., Coutts, G., . . . Varma, A. (2012). Accuracy of fluorodeoxyglucose positron emission tomography with computed tomography and magnetic resonance spectroscopy in differentiating between primary cerebral lymphoma and non- malignant CNS lesions in HIV infected patients. In HIV MEDICINE Vol. 13 (pp. 33). Retrieved from https://www.webofscience.com/
2011
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
2009
High risk of early failure of anti-retroviral therapy with Truvada/nevirapine and associated resistance mutations
Turtle, L., Reynolds, H., & Khoo, S. H. (2009). High risk of early failure of anti-retroviral therapy with Truvada/nevirapine and associated resistance mutations. In HIV MEDICINE Vol. 10 (pp. 19). Retrieved from https://www.webofscience.com/
2004
The relationship between nevirapine plasma concentrations and abnormal liver function tests
Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670
2003
Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring
Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029
2002
Pharmacokinetics of saquinavir co-administered with cimetidine
Boffito, M., Carriero, P., Trentini, L., Raiteri, R., Bonora, S., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetics of saquinavir co-administered with cimetidine. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(6), 1081-1084. doi:10.1093/jac/dkf232
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics
Boffito, M., Arnaudo, I., Raiteri, R., Bonora, S., Sinicco, A., Di Garbo, A., . . . Di Perri, G. (2002). Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS, 16(15), 2081-2083. doi:10.1097/00002030-200210180-00015
Simultaneous determination of rifampicin and efavirenz in plasma.
Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous determination of rifampicin and efavirenz in plasma.. Therapeutic drug monitoring, 24(5), 670-674. doi:10.1097/00007691-200210000-00015
The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects
Boffito, M., Hoggard, P. G., Reynolds, H. E., Bonora, S., Meaden, E. R., Sinicco, A., . . . Back, D. J. (2002). The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 54(3), 262-268. doi:10.1046/j.1365-2125.2002.01663.x
Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting
Boffito, M., Bonora, S., Raiteri, R., Reynolds, H. E., Hoggard, P. G., Sinicco, A., . . . Di Perri, G. (2002). Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. THERAPEUTIC DRUG MONITORING, 24(4), 574-576. doi:10.1097/00007691-200208000-00021
Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir
Clarke, S., Mulcahy, F., Bergin, C., Reynolds, H., Boyle, N., Barry, M., & Back, D. J. (2002). Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. CLINICAL INFECTIOUS DISEASES, 34(8), 1143-1145. doi:10.1086/339541
Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment
Boffito, M., Rossati, A., Reynolds, H. E., Hoggard, P. G., Back, D. J., & Di Perri, G. (2002). Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS RESEARCH AND HUMAN RETROVIRUSES, 18(5), 341-342. doi:10.1089/088922202753519115
Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354))
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Erratum: Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir (Journal of Antimicrobial Chemotherapy (2001) vol. 48 (351-354)). Journal of Antimicrobial Chemotherapy, 49(1), 227.
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir (vol 48, pg 351, 2001)
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2002). Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir (vol 48, pg 351, 2001). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 49(1), 227. doi:10.1093/jac/49.1.227
Simultaneous determination of rifampicin and efavirenz in plasma
Boffito, M., Tija, J., Reynolds, H. E., Hoggard, P. G., Bonora, S., Di Perri, G., & Back, D. J. (2002). Simultaneous determination of rifampicin and efavirenz in plasma. THERAPEUTIC DRUG MONITORING, 24(5), 670-674. doi:10.1097/00007691-200210000-00015
2001
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. CLINICAL INFECTIOUS DISEASES, 33(9), 1595-1597. doi:10.1086/322519
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men
Taylor, S., Reynolds, H., Sabin, C. A., Drake, S. M., White, D. J., Back, D. J., & Pillay, D. (2001). Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS, 15(15), 2051-2053. doi:10.1097/00002030-200110190-00022
Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir
Taylor, S., Back, D. J., Drake, S. M., Workman, J., Reynolds, H., Gibbons, S. E., . . . Pillay, D. (2001). Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 48(3), 351-354. doi:10.1093/jac/48.3.351
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G., & Back, D. J. (2001). The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(3), 213-217. doi:10.1046/j.1365-2125.2001.00342.x
Therapeutic drug monitoring of anti-HIV drugs
Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. OPTIMAL DOSE IDENTIFICATION, 1220, 145-160. doi:10.1016/S0531-5131(01)00294-1
2000
A pharmacokinetic study of indinavir (IDV) 600 mg bd and ritonavir (RTV) 200 mg bd in plasma and semen of HIV-1 infected men
Taylor, S., Reynolds, H., Drake, S. M., Stradling, C., White, D. J., Gibbons, S. E., & Back, D. J. (2000). A pharmacokinetic study of indinavir (IDV) 600 mg bd and ritonavir (RTV) 200 mg bd in plasma and semen of HIV-1 infected men. In AIDS Vol. 14 (pp. S96). Retrieved from https://www.webofscience.com/
The Liverpool Therapeutic Drug Monitoring Service - A summary of the service and examples of use in clinical practice
Gibbons, S. E., Reynolds, H. E., Tjia, J. F., Khoo, S. H., & Black, D. J. (2000). The Liverpool Therapeutic Drug Monitoring Service - A summary of the service and examples of use in clinical practice. In AIDS Vol. 14 (pp. S89-S90). Retrieved from https://www.webofscience.com/
Therapeutic drug monitoring in the management of subjects an the protease inhibitors nelfinavir and saquinavir: Results of the Roche UK TDM Service
Gibbons, S. E., Reynolds, H. E., Tjia, J. F., Khoo, S. H., Drake, J., & Back, J. (2000). Therapeutic drug monitoring in the management of subjects an the protease inhibitors nelfinavir and saquinavir: Results of the Roche UK TDM Service. In AIDS Vol. 14 (pp. S89). Retrieved from https://www.webofscience.com/